Cargando…
Targeting the Oncogenic TBX2 Transcription Factor With Chromomycins
The TBX2 transcription factor plays critical roles during embryonic development and it is overexpressed in several cancers, where it contributes to key oncogenic processes including the promotion of proliferation and bypass of senescence. Importantly, based on compelling biological evidences, TBX2 h...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7062867/ https://www.ncbi.nlm.nih.gov/pubmed/32195221 http://dx.doi.org/10.3389/fchem.2020.00110 |
_version_ | 1783504597349826560 |
---|---|
author | Sahm, Bianca Del B. Peres, Jade Rezende-Teixeira, Paula Santos, Evelyne A. Branco, Paola C. Bauermeister, Anelize Kimani, Serah Moreira, Eduarda A. Bisi-Alves, Renata Bellis, Claire Mlaza, Mihlali Jimenez, Paula C. Lopes, Norberto P. Machado-Santelli, Glaucia M. Prince, Sharon Costa-Lotufo, Leticia V. |
author_facet | Sahm, Bianca Del B. Peres, Jade Rezende-Teixeira, Paula Santos, Evelyne A. Branco, Paola C. Bauermeister, Anelize Kimani, Serah Moreira, Eduarda A. Bisi-Alves, Renata Bellis, Claire Mlaza, Mihlali Jimenez, Paula C. Lopes, Norberto P. Machado-Santelli, Glaucia M. Prince, Sharon Costa-Lotufo, Leticia V. |
author_sort | Sahm, Bianca Del B. |
collection | PubMed |
description | The TBX2 transcription factor plays critical roles during embryonic development and it is overexpressed in several cancers, where it contributes to key oncogenic processes including the promotion of proliferation and bypass of senescence. Importantly, based on compelling biological evidences, TBX2 has been considered as a potential target for new anticancer therapies. There has therefore been a substantial interest to identify molecules with TBX2-modulatory activity, but no such substance has been found to date. Here, we adopt a targeted approach based on a reverse-affinity procedure to identify the ability of chromomycins A(5) (CA(5)) and A(6) (CA(6)) to interact with TBX2. Briefly, a TBX2-DNA-binding domain recombinant protein was N-terminally linked to a resin, which in turn, was incubated with either CA(5) or CA(6). After elution, bound material was analyzed by UPLC-MS and CA(5) was recovered from TBX2-loaded resins. To confirm and quantify the affinity (K(D)) between the compounds and TBX2, microscale thermophoresis analysis was performed. CA(5) and CA(6) modified the thermophoretic behavior of TBX2, with a K(D) in micromolar range. To begin to understand whether these compounds exerted their anti-cancer activity through binding TBX2, we next analyzed their cytotoxicity in TBX2 expressing breast carcinoma, melanoma and rhabdomyosarcoma cells. The results show that CA(5) was consistently more potent than CA(6) in all tested cell lines with IC(50) values in the nM range. Of the cancer cell types tested, the melanoma cells were most sensitive. The knockdown of TBX2 in 501mel melanoma cells increased their sensitivity to CA(5) by up to 5 times. Furthermore, inducible expression of TBX2 in 501mel cells genetically engineered to express TBX2 in the presence of doxycycline, were less sensitive to CA(5) than the control cells. Together, the data presented in this study suggest that, in addition to its already recognized DNA-binding properties, CA(5) may be binding the transcription factor TBX2, and it can contribute to its cytotoxic activity. |
format | Online Article Text |
id | pubmed-7062867 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-70628672020-03-19 Targeting the Oncogenic TBX2 Transcription Factor With Chromomycins Sahm, Bianca Del B. Peres, Jade Rezende-Teixeira, Paula Santos, Evelyne A. Branco, Paola C. Bauermeister, Anelize Kimani, Serah Moreira, Eduarda A. Bisi-Alves, Renata Bellis, Claire Mlaza, Mihlali Jimenez, Paula C. Lopes, Norberto P. Machado-Santelli, Glaucia M. Prince, Sharon Costa-Lotufo, Leticia V. Front Chem Chemistry The TBX2 transcription factor plays critical roles during embryonic development and it is overexpressed in several cancers, where it contributes to key oncogenic processes including the promotion of proliferation and bypass of senescence. Importantly, based on compelling biological evidences, TBX2 has been considered as a potential target for new anticancer therapies. There has therefore been a substantial interest to identify molecules with TBX2-modulatory activity, but no such substance has been found to date. Here, we adopt a targeted approach based on a reverse-affinity procedure to identify the ability of chromomycins A(5) (CA(5)) and A(6) (CA(6)) to interact with TBX2. Briefly, a TBX2-DNA-binding domain recombinant protein was N-terminally linked to a resin, which in turn, was incubated with either CA(5) or CA(6). After elution, bound material was analyzed by UPLC-MS and CA(5) was recovered from TBX2-loaded resins. To confirm and quantify the affinity (K(D)) between the compounds and TBX2, microscale thermophoresis analysis was performed. CA(5) and CA(6) modified the thermophoretic behavior of TBX2, with a K(D) in micromolar range. To begin to understand whether these compounds exerted their anti-cancer activity through binding TBX2, we next analyzed their cytotoxicity in TBX2 expressing breast carcinoma, melanoma and rhabdomyosarcoma cells. The results show that CA(5) was consistently more potent than CA(6) in all tested cell lines with IC(50) values in the nM range. Of the cancer cell types tested, the melanoma cells were most sensitive. The knockdown of TBX2 in 501mel melanoma cells increased their sensitivity to CA(5) by up to 5 times. Furthermore, inducible expression of TBX2 in 501mel cells genetically engineered to express TBX2 in the presence of doxycycline, were less sensitive to CA(5) than the control cells. Together, the data presented in this study suggest that, in addition to its already recognized DNA-binding properties, CA(5) may be binding the transcription factor TBX2, and it can contribute to its cytotoxic activity. Frontiers Media S.A. 2020-03-03 /pmc/articles/PMC7062867/ /pubmed/32195221 http://dx.doi.org/10.3389/fchem.2020.00110 Text en Copyright © 2020 Sahm, Peres, Rezende-Teixeira, Santos, Branco, Bauermeister, Kimani, Moreira, Bisi-Alves, Bellis, Mlaza, Jimenez, Lopes, Machado-Santelli, Prince and Costa-Lotufo. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Chemistry Sahm, Bianca Del B. Peres, Jade Rezende-Teixeira, Paula Santos, Evelyne A. Branco, Paola C. Bauermeister, Anelize Kimani, Serah Moreira, Eduarda A. Bisi-Alves, Renata Bellis, Claire Mlaza, Mihlali Jimenez, Paula C. Lopes, Norberto P. Machado-Santelli, Glaucia M. Prince, Sharon Costa-Lotufo, Leticia V. Targeting the Oncogenic TBX2 Transcription Factor With Chromomycins |
title | Targeting the Oncogenic TBX2 Transcription Factor With Chromomycins |
title_full | Targeting the Oncogenic TBX2 Transcription Factor With Chromomycins |
title_fullStr | Targeting the Oncogenic TBX2 Transcription Factor With Chromomycins |
title_full_unstemmed | Targeting the Oncogenic TBX2 Transcription Factor With Chromomycins |
title_short | Targeting the Oncogenic TBX2 Transcription Factor With Chromomycins |
title_sort | targeting the oncogenic tbx2 transcription factor with chromomycins |
topic | Chemistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7062867/ https://www.ncbi.nlm.nih.gov/pubmed/32195221 http://dx.doi.org/10.3389/fchem.2020.00110 |
work_keys_str_mv | AT sahmbiancadelb targetingtheoncogenictbx2transcriptionfactorwithchromomycins AT peresjade targetingtheoncogenictbx2transcriptionfactorwithchromomycins AT rezendeteixeirapaula targetingtheoncogenictbx2transcriptionfactorwithchromomycins AT santosevelynea targetingtheoncogenictbx2transcriptionfactorwithchromomycins AT brancopaolac targetingtheoncogenictbx2transcriptionfactorwithchromomycins AT bauermeisteranelize targetingtheoncogenictbx2transcriptionfactorwithchromomycins AT kimaniserah targetingtheoncogenictbx2transcriptionfactorwithchromomycins AT moreiraeduardaa targetingtheoncogenictbx2transcriptionfactorwithchromomycins AT bisialvesrenata targetingtheoncogenictbx2transcriptionfactorwithchromomycins AT bellisclaire targetingtheoncogenictbx2transcriptionfactorwithchromomycins AT mlazamihlali targetingtheoncogenictbx2transcriptionfactorwithchromomycins AT jimenezpaulac targetingtheoncogenictbx2transcriptionfactorwithchromomycins AT lopesnorbertop targetingtheoncogenictbx2transcriptionfactorwithchromomycins AT machadosantelliglauciam targetingtheoncogenictbx2transcriptionfactorwithchromomycins AT princesharon targetingtheoncogenictbx2transcriptionfactorwithchromomycins AT costalotufoleticiav targetingtheoncogenictbx2transcriptionfactorwithchromomycins |